Eli Lilly just shared some new information. That data suggests it has an advantage against Novo Nordisk in a key market.
Chipotle is raising its U.S. prices to offset inflation and to compensate for a promise to increase portion sizes.
Eli Lilly and Company announced earlier this week that its popular obesity drug, Zepbound (tirzepatide) outperformed rival ...
Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 524.46% and ...
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), AbbVie ...
It didn’t take long for the shine to come off one of biotech’s recent IPO success stories, with BioAge Labs scrapping a phase ...
Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products.
The FDA put both peptides on its shortage list in 2022. Semaglutide is still on that list, while the FDA lifted its shortage ...
Joe Breen, 38, is one of thousands of people whose experiences with GLP-1s such as Ozempic and Wegovy have radically changed their relationship with alcohol. Here, we unpack the latest research on GLP ...
The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli Lilly’s popular weight loss medication Zepbound and diabetes drug Mounjaro.
Lilly announces a $3B expansion in Wisconsin to boost production of weight loss drugs and strengthen its position in the ...